Kantar Health Report issue

For profit Phase 3
Founded: New York NY United States (2009)
Status: Acquired by Cerner (2020)

Organization Overview

First Clinical Trial
2014
NCT02246127
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (3)

everolimus (zortress) (1 trial)

fluorouracil (efudex) (1 trial)

streptozotocin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neuroendocrine Tumors (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 3